Prime Time for Five Prime in IPO Filing
By Marie Powers
Monday, July 29, 2013
Protein and antibody drug developer Five Prime Therapeutics Inc. became the newest member of the class of 2013 biotech initial public offerings (IPOs) by filing an S-1 seeking to raise up to $60 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.